Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

Paul J. Hampel; Kari G. Rabe; Timothy G. Call; Wei Ding; Jose F. Leis; Saad S. Kenderian; Eli Muchtar; Yucai Wang; Amber B. Koehler; Ricardo Parrondo; Susan M. Schwager; Min Shi; Esteban Braggio; Susan L. Slager; Neil E. Kay; Sameer A. Parikh

doi:10.1111/bjh.18357

Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Min Shi, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-naïve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.

Original language	English (US)
Pages (from-to)	239-244
Number of pages	6
Journal	British journal of haematology
Volume	199
Issue number	2
DOIs	https://doi.org/10.1111/bjh.18357
State	Published - Oct 2022

Keywords

chronic lymphocytic leukaemia
ibrutinib
treatment
venetoclax

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.18357

Cite this

Hampel, P. J., Rabe, K. G., Call, T. G., Ding, W., Leis, J. F., Kenderian, S. S., Muchtar, E., Wang, Y., Koehler, A. B., Parrondo, R., Schwager, S. M., Shi, M., Braggio, E., Slager, S. L., Kay, N. E., & Parikh, S. A. (2022). Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. British journal of haematology, 199(2), 239-244. https://doi.org/10.1111/bjh.18357

Hampel, PJ, Rabe, KG, Call, TG, Ding, W, Leis, JF, Kenderian, SS, Muchtar, E, Wang, Y, Koehler, AB, Parrondo, R, Schwager, SM, Shi, M, Braggio, E , Slager, SL , Kay, NE & Parikh, SA 2022, 'Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia', British journal of haematology, vol. 199, no. 2, pp. 239-244. https://doi.org/10.1111/bjh.18357

@article{cbe0f25498954c9a8eeb444085c06816,

title = "Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia",

abstract = "Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-na{\"i}ve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.",

keywords = "chronic lymphocytic leukaemia, ibrutinib, treatment, venetoclax",

author = "Hampel, {Paul J.} and Rabe, {Kari G.} and Call, {Timothy G.} and Wei Ding and Leis, {Jose F.} and Kenderian, {Saad S.} and Eli Muchtar and Yucai Wang and Koehler, {Amber B.} and Ricardo Parrondo and Schwager, {Susan M.} and Min Shi and Esteban Braggio and Slager, {Susan L.} and Kay, {Neil E.} and Parikh, {Sameer A.}",

note = "Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

month = oct,

doi = "10.1111/bjh.18357",

language = "English (US)",

volume = "199",

pages = "239--244",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

AU - Hampel, Paul J.

AU - Rabe, Kari G.

AU - Call, Timothy G.

AU - Ding, Wei

AU - Leis, Jose F.

AU - Kenderian, Saad S.

AU - Muchtar, Eli

AU - Wang, Yucai

AU - Koehler, Amber B.

AU - Parrondo, Ricardo

AU - Schwager, Susan M.

AU - Shi, Min

AU - Braggio, Esteban

AU - Slager, Susan L.

AU - Kay, Neil E.

AU - Parikh, Sameer A.

PY - 2022/10

Y1 - 2022/10

N2 - Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-naïve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.

AB - Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-naïve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.

KW - chronic lymphocytic leukaemia

KW - ibrutinib

KW - treatment

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85134034197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134034197&partnerID=8YFLogxK

U2 - 10.1111/bjh.18357

DO - 10.1111/bjh.18357

M3 - Article

C2 - 35841338

AN - SCOPUS:85134034197

SN - 0007-1048

VL - 199

SP - 239

EP - 244

JO - British journal of haematology

JF - British journal of haematology

IS - 2

ER -

Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this